Bavarian Nordic, a leading vaccine manufacturer known for its mpox vaccine supply in the U.S. and EU, is poised for acquisition by a consortium led by Nordic Capital and Permira in a deal valued around $3 billion. The acquisition reflects strategic growth plans involving portfolio expansion and operational scaling under private ownership. The board unanimously recommended shareholders accept the premium offer, which embodies a significant transaction in the vaccine sector in 2025.